Phase Ia,first-in-human study of AbGn-107,a novel antibody-drug conjugate(ADC),in patients with gastric,colorectal,pancreatic,or biliary cancers
PublishedAmerican Society of Clinical Oncology (ASCO)
Author (s)Andrew H.Ko,Andrew L.Coveler,Benjamin L.Schlechter,Tanios S.Bekaii-Saab,Brian M.Wolpin,Jeffery W.Clark,Bruno Bockorny,Yi-Lin Cheng,Ting-Ying Cheng,Peter Langecker and Shih-Yao Lin